NASDAQ:NH - NantHealth Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.02
▼ -0.03 (-2.86%)

This chart shows the closing price for NH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NantHealth Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NantHealth in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.02.

This chart shows the closing price for NH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in NantHealth. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/26/2019CowenSet Price TargetBuy$1.00Low
7/3/2018Canaccord GenuityReiterated RatingHoldLow
3/21/2018Jefferies Financial GroupSet Price TargetBuy$5.00High
3/20/2018CowenReiterated RatingBuy$4.50Low
11/17/2017Canaccord GenuityLower Price TargetBuy ➝ Buy$6.00 ➝ $5.00N/A
9/28/2017Jefferies Financial GroupReiterated RatingBuy$5.00Low
8/23/2017Jefferies Financial GroupLower Price TargetBuy$5.50 ➝ $5.00Medium
8/21/2017Canaccord GenuityReiterated RatingBuy$8.00 ➝ $6.00Low
6/19/2017Jefferies Financial GroupReiterated RatingBuy$8.00 ➝ $5.50Low
4/3/2017Cantor FitzgeraldLower Price TargetOverweight$15.00 ➝ $13.00High
4/1/2017FBR & Co.Set Price TargetBuy$13.00High
3/31/2017Jefferies Financial GroupReiterated RatingBuy$16.00 ➝ $8.00Low
3/31/2017Canaccord GenuityReiterated RatingBuy$10.00High
3/6/2017Cantor FitzgeraldReiterated RatingOverweight$15.00N/A
2/24/2017Canaccord GenuityReiterated RatingBuy$16.00N/A
2/3/2017Canaccord GenuityReiterated RatingBuy$16.00N/A
1/27/2017Cantor FitzgeraldReiterated RatingOverweight$15.00N/A
1/5/2017Cantor FitzgeraldInitiated CoverageOverweight$17.00N/A
1/3/2017Canaccord GenuityReiterated RatingBuy$16.00N/A
(Data available from 12/4/2016 forward)

News Sentiment Rating

0.90 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2021
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/5/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2021
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2021

Current Sentiment

  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
NantHealth logo
NantHealth, Inc. is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer. Its solutions include empower treatment decisions; improve patient outcomes; validate treatment options; enable high-quality care; lower costs; ensure appropriate reimbursement; and streamline implementation and deployment. The company was founded by Patrick Soon-Shiong in July 2010 and is headquartered in Culver City, CA.
Read More

Today's Range

Now: $1.02
Low: $1.00
High: $1.05

50 Day Range

MA: $1.57
Low: $1.02
High: $1.85

52 Week Range

Now: $1.02
Low: $1.00
High: $6.60

Volume

78,104 shs

Average Volume

272,804 shs

Market Capitalization

$117.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of NantHealth?

The following sell-side analysts have issued research reports on NantHealth in the last year: Zacks Investment Research.
View the latest analyst ratings for NH.

What is the current price target for NantHealth?

0 Wall Street analysts have set twelve-month price targets for NantHealth in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NantHealth in the next year.
View the latest price targets for NH.

What is the current consensus analyst rating for NantHealth?

NantHealth currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NH.

What other companies compete with NantHealth?

How do I contact NantHealth's investor relations team?

NantHealth's physical mailing address is 9920 JEFFERSON BLVD, CULVER CITY CA, 90232. The company's listed phone number is (310) 883-1300 and its investor relations email address is [email protected] The official website for NantHealth is www.nanthealth.com.